INDEME: A targeted approach for depigmentation disorders

AQUITAINE SCIENCE TRANSFERT



27 Février 2018

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

APPLICATIONS

Therapy dedicated to depigmentation disorders associated with inflammatory skin diseases such as:

  • Vitiligo: most common depigmenting disorder (0.5-1% of the world population)
    • Stigma and major negative impact on patients’ quality of life
    • No cure nor way of restricting the spread of the disease reported so far
  • Sclerodermia, Psoriasis, Atopic dermatitis: often associated with pigmentation disorders responsible of impact on quality of life

DESCRIPTION

  • Identification of a core molecule X1 involved in melanocytes detachment responsible for depigmentation in vitiligo and post-inflammatory skin disorders
    • Ex vivo analysis
      • Higher X1 expression in vitiligo patients’ skin and sera compared to healthy subjects−Vitiligo patients: Positive correlation between X1 level and the body surface area involved
    • POC in vitro:
      • Inhibitors targeting X1 prevent melanocyte detachment in a 3D-induced depigmentation model

BENEFITS

  • Development of the first targeted therapy dedicated to inflammatory skin disorders with high unmet medical needs
  • Near-orphan status for drug development
  • Application to diverse inflammatory skin disorders associated with depigmentation
    • Vitiligo
    • Scleroderma, Psoriasis and Atopic Dermatitis

IP

This technology is protected by a patent application

Download the offer Download the offer

Newsletter